Patent Ductus Arteriosus (PDA) Ligation — Cost, Top Hospitals & Success Rates | MyMedicPlus

The ductus arteriosus is a normal and essential fetal vascular structure — a muscular arterial channel connecting the main pulmonary artery to the descending aorta (just distal to the left subclavian artery). In fetal life, it diverts blood away from the high-resistance, fluid-filled fetal lungs directly into the systemic circulation, bypassing the pulmonary vascular bed. At birth, as the lungs inflate and pulmonary vascular resistance drops precipitously, rising oxygen tension and declining prostaglandin E2 (PGE2) levels trigger functional closure of the ductus arteriosus within 12–24 hours, with anatomical closure (ligamentum arteriosum) typically complete by 2–3 weeks of postnatal life in healthy term infants.

Patent Ductus Arteriosus (PDA) refers to the pathological persistence of this vessel beyond the normal closure period. In term neonates and older patients, PDA generates a left-to-right shunt — oxygenated blood flows from the high-pressure systemic circulation (aorta) into the lower-pressure pulmonary artery, recirculating through the lungs. The haemodynamic consequences include pulmonary overcirculation (causing tachypnoea, respiratory distress), left ventricular volume overload (leading to cardiac enlargement and failure), and a "ductal steal" phenomenon — diastolic reversal of flow in the descending aorta compromises perfusion of the gut (necrotising enterocolitis risk), kidneys, and brain.

PDA is particularly common in preterm infants — it complicates up to 70% of very-low-birth-weight (VLBW, <1,500 g) infants and nearly 80% of extremely-low-birth-weight (<1,000 g) infants. The incidence is inversely related to gestational age. PDA in premature infants is the leading cause of pulmonary haemorrhage, a complication of surfactant therapy in respiratory distress syndrome (RDS). However, the evidence base for active treatment of haemodynamically significant PDA in premature infants has evolved considerably, and expectant management is now the default strategy in many neonatal intensive care units.

In older infants, children, and adults, isolated PDA accounts for approximately 5–10% of all congenital heart disease. Large untreated PDAs lead to pulmonary arterial hypertension, left ventricular failure, and ultimately Eisenmenger syndrome (reversal of shunt to right-to-left with cyanosis) — outcomes that are largely preventable with timely intervention.

The clinical significance of PDA ranges from incidental finding to life-threatening cardiovascular compromise, and treatment decisions are driven by haemodynamic impact:

• Haemodynamically Significant PDA in Preterm Infants: Defined by clinical signs (bounding pulses, active precordium, widened pulse pressure, continuous machinery murmur in older infants), echocardiographic criteria (ductal diameter, left atrium:aorta ratio >1.5, reversed diastolic flow in the descending aorta or mesenteric arteries), and clinical deterioration (increasing respiratory support requirements, inability to wean from mechanical ventilation, pulmonary haemorrhage).
• Symptomatic PDA in Term Neonates and Infants: Large PDAs causing heart failure symptoms — tachypnoea, poor feeding, faltering growth, recurrent chest infections, and biventricular enlargement on echocardiography — require treatment. Small asymptomatic PDAs may close spontaneously over months to years.
• PDA in Children and Adults: Any PDA with a left-to-right shunt causing pulmonary overcirculation (Qp:Qs >1.5:1) or left ventricular volume overload on echocardiography warrants closure, even if asymptomatic, to prevent long-term sequelae. Silent PDAs (detected only on colour Doppler without auscultatory murmur) remain controversial — current ACC/AHA guidelines recommend closure to eliminate infective endarteritis risk and prevent silent pulmonary hypertension.
• Duct-Dependent Congenital Heart Disease: Conversely, certain critical CHD lesions (pulmonary atresia, critical pulmonary stenosis, tricuspid atresia, interrupted aortic arch, hypoplastic left heart syndrome) are duct-dependent — their systemic or pulmonary circulation relies on ductal patency. In these patients, the ductus arteriosus must be deliberately kept open with continuous prostaglandin E1 (alprostadil) infusion until definitive palliation or repair, and ductal stenting is used as part of staged palliation strategies (Blalock-Taussig shunt alternative).
• Eisenmenger PDA: Advanced pulmonary arterial hypertension with shunt reversal is a contraindication to PDA closure. Pulmonary vasodilator therapy (sildenafil, bosentan) may be used, and transplantation is the only curative option.

The decision to treat PDA — and which treatment modality to use — requires careful haemodynamic, echocardiographic, and clinical assessment:

• Echocardiographic Assessment: Two-dimensional and colour Doppler echocardiography is the diagnostic gold standard for PDA. Key parameters include: ductal diameter (small <1.5 mm, moderate 1.5–3 mm, large >3 mm or >1.5 mm/kg), shunt direction (L→R, bidirectional, R→L), left atrial:aortic root ratio (LA:Ao), pulmonary artery pressure estimation, and left ventricular dimensions and function. Echocardiographic criteria alone are insufficient for treatment decisions — clinical context is essential.
• Gestational Age and Birth Weight: In extremely preterm infants (<28 weeks), expectant management is now preferred by most neonatal units — many haemodynamically significant PDAs close spontaneously over weeks without intervention, and aggressive pharmacological treatment may not improve outcomes (TRIOCAPI trial, Hundscheid 2021). Treatment is reserved for infants with deteriorating respiratory status, pulmonary haemorrhage, or failure to wean from ventilation.
• Body Weight for Transcatheter Closure: The Amplatzer Piccolo Occluder (Abbott) received FDA approval in 2019 for transcatheter PDA closure in premature infants as young as 3 days and as small as 700 grams — representing a paradigm shift from surgical to catheter-based treatment even in extremely small preterm infants. Catheter laboratory availability and interventional cardiology expertise are prerequisites.
• Pulmonary Vascular Resistance: In older patients undergoing elective closure, pulmonary vascular resistance must be calculated (ideally <6 Wood units indexed) to confirm reversibility and suitability for closure. Acute vasodilator testing may be required if PAH is suspected.
• Contraindications to Medical Treatment: NSAIDs (ibuprofen, indomethacin) are contraindicated in significant renal impairment, active bleeding (including intracranial haemorrhage or pulmonary haemorrhage), thrombocytopenia (<50,000/mL), necrotising enterocolitis, hyperbilirubinaemia, and severe coagulopathy. Paracetamol (acetaminophen) has a more favourable safety profile and is increasingly preferred as initial pharmacotherapy.

PDA management encompasses three principal treatment strategies:

• Expectant / Conservative Management: Recent evidence, including the large multicentre TRIOCAPI trial (Hundscheid et al., JAMA Pediatr 2021), showed that in preterm infants <28 weeks, expectant management (no active PDA treatment) produced similar neonatal outcomes (death, chronic lung disease, intraventricular haemorrhage, NEC) to early ibuprofen treatment, with substantially lower rates of drug side effects. Many NICUs now adopt a "wait and watch" approach with supportive measures (fluid restriction, respiratory optimisation) as the first-line strategy in stable premature infants.
• Medical Closure — Indomethacin: A non-selective COX inhibitor that reduces prostaglandin synthesis, increasing vascular smooth muscle tone in the ductus. Standard dosing: IV indomethacin 0.1–0.25 mg/kg, 3 doses at 12–24 hour intervals. Ductal closure rates: 70–80% after first course. Associated with reduced renal blood flow, oliguria, intestinal and cerebral vasoconstriction, and electrolyte disturbances. Has an established track record (used since 1970s) and also reduces rates of severe intraventricular haemorrhage (Grade III–IV IVH) as an independent neuroprotective effect.
• Medical Closure — Ibuprofen: A selective COX-2 inhibitor with similar ductal closure efficacy to indomethacin (75–80% closure rate) but with superior renal safety profile — fewer episodes of oliguria and creatinine elevation. Available as IV lysine-ibuprofen or oral ibuprofen suspension. Standard dose: 10 mg/kg initial dose, then 5 mg/kg at 24 and 48 hours. Has largely replaced indomethacin as the preferred NSAID for PDA closure in many European and Asian NICUs.
• Medical Closure — Paracetamol (Acetaminophen): The most important pharmacological development in PDA management in the past decade. Paracetamol inhibits cyclooxygenase (COX) via a different mechanism than traditional NSAIDs, and avoids their renal, intestinal, and platelet side effects. The TRIOCAPI trial (2021) compared oral paracetamol vs indomethacin vs placebo as first-line treatment — paracetamol achieved ductal closure rates of 57–74% with a significantly more favourable adverse effect profile. IV paracetamol dose: 15 mg/kg 6-hourly for 3–7 days. NICE guidance (2021) and several NICU consortia now recommend paracetamol as the first-line pharmacological agent for PDA closure due to its safety profile.
• Transcatheter Closure — Amplatzer Piccolo Occluder: A catheter-delivered nitinol mesh device delivered via the femoral vein under fluoroscopic and echocardiographic guidance in the cardiac catheterisation laboratory. The Piccolo device (specifically designed for very small PDAs) can be delivered through a 4F sheath, enabling treatment of extremely small preterm infants. Ductal closure rates: >98% at 6 months. The PATENT trial and PDA-PILOT registry demonstrated safety and efficacy in infants as small as 700 g. Increasingly displacing surgery as the preferred treatment for persistent PDA after failed pharmacotherapy.
• Surgical Ligation — Video-Assisted Thoracoscopic Surgery (VATS): Minimally invasive thoracoscopic ligation using 3–4 ports in the left lateral decubitus position. The ductus arteriosus is identified, dissected free, and ligated with a surgical clip (Hemoclip or titanium clip). VATS ligation has equivalent closure rates to open thoracotomy (>98%) with faster recovery, shorter chest drain times, shorter hospital stay, and reduced risk of musculoskeletal complications (thoracotomy scoliosis, shoulder girdle weakness). Requires general anaesthesia and single-lung ventilation capability in a surgical centre.
• Surgical Ligation — Open Thoracotomy: Left posterior lateral thoracotomy remains the alternative when VATS is not available or in complex anatomical situations. The ductus is approached through the 3rd or 4th intercostal space, double-ligated with silk sutures, or clipped and divided. Historically the only available surgical technique; now increasingly replaced by VATS and transcatheter approaches.
• Ductal Stenting: For duct-dependent CHD (e.g., pulmonary atresia with intact ventricular septum, tricuspid atresia), stenting of the ductus arteriosus with a coronary bare-metal stent delivered via catheter maintains ductal patency as a bridge to or as an alternative to Blalock-Taussig-Thomas (BTT) shunt palliation. Ductal stenting is associated with lower morbidity than BTT shunt in some series and has become part of staged palliation protocols for univentricular heart disease in specialised congenital cardiac centres.

Timely and appropriate PDA closure provides significant haemodynamic and clinical benefits:

• Respiratory Improvement: Closure of a haemodynamically significant PDA in premature infants reduces pulmonary blood flow, allowing recruitment of collapsed alveoli, improvement in lung compliance, and facilitation of ventilator weaning. In term infants and children, elimination of the left-to-right shunt resolves tachypnoea, recurrent pulmonary infections, and exercise intolerance.
• Prevention of Heart Failure: Prolonged large PDA causes progressive left ventricular dilatation and failure. Early closure prevents LV remodelling and restores normal ventricular dimensions and function on echocardiography.
• Pulmonary Hypertension Prevention: Chronic pulmonary overcirculation from an untreated large PDA leads to pulmonary vascular remodelling and irreversible pulmonary arterial hypertension (Eisenmenger syndrome) within the first decade of life if untreated. Closure in infancy or early childhood prevents this complication.
• Protection Against Infective Endarteritis: PDA creates turbulent flow at the ductal orifice, predisposing to bacterial endarteritis — a risk that persists even with small PDAs. Closure eliminates this risk. All symptomatic PDAs, and most asymptomatic PDAs beyond infancy, are therefore closed electively.
• Transcatheter Advantages: The Amplatzer Piccolo and similar devices allow PDA closure without general anaesthesia in older infants/children, in a day-case or short-stay setting, with no thoracic incision, faster recovery, and cosmetically superior outcomes.
• Growth and Neurodevelopment: In premature infants, resolution of haemodynamically significant PDA is associated with improved somatic growth and, in some studies, better neurodevelopmental outcomes — likely through improved cerebral perfusion and reduced need for prolonged mechanical ventilation and its associated lung injury.

Each treatment modality carries specific risks that must be considered in the context of gestational age, haemodynamic status, and the risks of untreated PDA:

• Risks of Medical Treatment (NSAIDs/Paracetamol): Indomethacin and ibuprofen cause renal vasoconstriction — oliguria, elevated creatinine, and hyponatraemia are common (20–40%). Intestinal vasoconstriction with indomethacin may increase NEC risk (though evidence is conflicting). Both NSAIDs affect platelet function and prolong bleeding time, increasing risk of pulmonary and intracranial haemorrhage in thrombocytopaenic preterm infants. Paracetamol's hepatotoxicity risk at the doses used for PDA closure is theoretical but has not been observed in clinical trials.
• Ductal Reopening after Medical Treatment: After successful pharmacological closure, the ductus reopens in 20–35% of very preterm infants, necessitating a second course of medication or escalation to transcatheter/surgical closure.
• Transcatheter Complications: Device embolisation (<1%), residual shunting (<5% at 12 months), left pulmonary artery stenosis due to device protrusion (2–4% with Piccolo device in small infants), vascular access complications (femoral artery spasm, haematoma), and arrhythmias during catheter manipulation. In very small premature infants (<1 kg), femoral artery access remains technically demanding and carries ischaemia risk.
• Surgical Ligation Risks: Inadvertent ligation of the left pulmonary artery or descending aorta is a rare but catastrophic complication occurring in approximately 0.5% of operations, particularly in extremely preterm infants where the ductus is large relative to surrounding structures. Other surgical risks include pneumothorax, chylothorax (thoracic duct injury, 1–3%), vocal cord palsy (left recurrent laryngeal nerve injury, 1–5%), and wound infection. Post-operative cardiovascular compromise from acute left-to-right shunt elimination can cause transient hypotension in infants with severely dilated left ventricles.
• Over-Treatment Concern: Evidence from several large cohort studies and the TRIOCAPI trial suggests that in extremely preterm infants, aggressive pharmacological treatment of all haemodynamically significant PDAs does not improve neurodevelopmental or respiratory outcomes compared to expectant management. This has prompted a major shift toward selective, individualised treatment approaches rather than routine pharmacological closure.

Post-treatment monitoring depends on the modality used and the age and clinical status of the patient:

• After Medical Treatment in Preterm Infants: Serial echocardiography at 24–48 hours after each course of medication confirms ductal closure or identifies reopening. Renal function (creatinine, urea, urine output), electrolytes, and full blood count are monitored daily during pharmacotherapy. If two courses of medication fail to close the ductus and the infant remains haemodynamically compromised, referral to a paediatric cardiac catheterisation centre for Piccolo device placement is recommended.
• After Transcatheter Closure: Echocardiography is performed before discharge (typically within 24 hours of the procedure) to confirm device position, exclude residual shunt, and assess left pulmonary artery flow velocity. Follow-up echocardiography is repeated at 1 month, 3 months, and 12 months. If residual shunt is identified at 3 months (most close spontaneously by 12 months), continued surveillance is warranted.
• After Surgical Ligation: Chest drain is usually removed within 24–48 hours; post-operative chest X-ray confirms lung expansion. Echocardiography before discharge confirms complete ductal closure and absence of complications (left pulmonary artery stenosis, left ventricular function). Left recurrent laryngeal nerve injury is assessed by direct laryngoscopy if hoarse cry or feeding difficulties arise post-operatively.
• Long-Term Follow-Up in Children and Adults: After successful PDA closure in childhood, most patients require no ongoing cardiac surveillance beyond a one-year follow-up echocardiogram. Those who develop residual pulmonary hypertension or who underwent closure late in the course of significant PAH require ongoing specialist monitoring. ACC/AHA 2018 Congenital Heart Disease guidelines recommend lifelong follow-up in CHD centres for patients with complex associated lesions.
• Neurodevelopmental Follow-Up: All preterm infants — regardless of PDA treatment status — require structured neurodevelopmental follow-up at 2, 5, and 8 years per BAPM/NICE guidance for premature birth outcomes. PDA and its treatment are among multiple contributors to neurodevelopmental risk in this population.

PDA treatment costs span a wide range depending on the intervention, setting, and patient complexity:

• Medical Treatment (Indomethacin/Ibuprofen/Paracetamol): Drug costs are modest — IV indomethacin costs approximately USD 50–200 per course in developed markets; IV ibuprofen GBP 80–200 per course; IV or oral paracetamol for PDA closure (off-label dosing) is extremely inexpensive (USD 5–20 per course). However, NICU nursing and monitoring costs dominate the economic picture in preterm management, where daily NICU costs average USD 3,000–6,000 per day in the US.
• Transcatheter Closure Device: The Amplatzer Piccolo Occluder device costs approximately USD 3,500–6,000 per device in the US. Total procedure cost including catheterisation laboratory time, consumables, anaesthesia, and short stay: USD 12,000–30,000. In India, transcatheter PDA closure costs USD 2,500–5,000 at JCI-accredited cardiac centres — driving significant medical tourism from lower-income countries.
• Surgical Ligation: VATS ligation at UK NHS hospitals is covered under NHS tariff. Private VATS ligation in the UK: GBP 8,000–15,000. In the US, surgical PDA ligation costs USD 20,000–60,000 including surgeon, anaesthesia, operating theatre, and NICU post-operative care. In India, surgical PDA ligation at specialist cardiac centres: USD 4,000–10,000.
• Cost of Untreated PDA: Prolonged haemodynamically significant PDA extends ventilator dependency, NICU duration, and risk of complications (NEC, IVH, pulmonary haemorrhage) — each of which carries major cost implications. One episode of NEC in a preterm infant costs approximately USD 30,000–75,000 in additional care; Grade III–IV IVH substantially increases long-term disability and healthcare costs.
• Insurance Coverage: PDA closure — medical, transcatheter, and surgical — is covered by all major insurance systems as a medically necessary intervention for symptomatic congenital heart disease. NICU coverage for premature infants includes pharmacological PDA management costs under neonatal care billing.

The management of PDA has evolved substantially, with alternatives to traditional approaches increasingly evidence-based:

• Conservative (Expectant) Management: The strongest shift in PDA management has been toward watchful waiting in stable preterm infants. Multiple observational studies and the TRIOCAPI RCT demonstrate that many haemodynamically significant PDAs in preterm infants close spontaneously without pharmacotherapy, and aggressive routine treatment does not improve survival or neurodevelopmental outcomes. Conservative management includes fluid restriction, optimised respiratory support, and close echocardiographic surveillance. This approach avoids NSAID side effects and may reduce rates of chronic lung disease.
• Oral Ibuprofen: Oral ibuprofen suspension (10 mg/kg then 5 mg/kg at 24 and 48 hours) achieves ductal closure rates similar to IV ibuprofen (80–85%) and is significantly cheaper, making it the preferred agent in resource-limited settings. GI absorption is adequate when given enterally in haemodynamically stable preterm infants.
• High-Dose Oral Paracetamol: Studies have evaluated oral paracetamol 15 mg/kg 6-hourly for 3–7 days as an alternative to IV formulation. Efficacy is comparable to IV administration when enteral feeds are tolerated. A systematic review (Jasani et al., Cochrane 2018) found similar closure rates to ibuprofen with significantly fewer adverse effects, supporting paracetamol as a first-line agent.
• Catheter-Based Occlusion in Older Patients: For PDAs in older children and adults, the full range of transcatheter devices is available including the Amplatzer Duct Occluder I and II, Occlutech PDA Occluder, and MVSM (muscular VSD occluder) for very small tubular PDAs. Vascular plug systems are used for small PDAs. Transcatheter closure is the preferred approach in patients over 6 months of age in most congenital heart centres globally — surgical closure is rarely required in this age group.
• Hybrid Procedures: In extremely small infants where neither catheter access nor open surgery is ideal, hybrid operating theatre procedures combine transcatheter device delivery via direct surgical access to the main pulmonary artery (hybrid intraoperative device placement) with the safety of surgical backup.
• Indomethacin Prophylaxis: In extremely preterm infants (<28 weeks), prophylactic indomethacin (within 6 hours of birth, before echocardiographic confirmation of PDA) reduces the rate of symptomatic PDA and severe IVH, but does not improve survival or neurodevelopmental outcomes in landmark trials (TIPP trial). Its routine use has declined as expectant management becomes standard.